Novartis Prepares For Diovan Patent Expiries; Looks To New Product Launches

Novartis is shifting its marketing muscle away from the mega-drug Diovan and encouraging new hypertensive patients to take Tekturna or Exforge in hopes of forestalling generic competition that will begin to surface in two years, according to Joe Jimenez, who heads the pharmaceuticals business